“Hit Hard. Hit Fast. Precision Power Against ESBL, AmpC, KPC OXA-48 & CRE”.

ZIDAVI (Ceftazidime/Avibactam) 2.5 g is a potent fixed-dose combination for multidrug- resistant (MDR) Gram-negative infections. Highly effective as monotherapy against KPC- and OXA-48-producing carbapenem-resistant Enterobacterales (CRE). When combined with Aztam (Aztreonam), it provides Pakistan’s only complete carbapenem- and colistin-sparing solution for NDM/MBL-producing pathogens.

Indications:

Complicated intra-abdominal infections (cIAI) (with metronidazole), complicated urinary tract infections (cUTI) including pyelonephritis, hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and associated bacteremia. Preferred option for KPC-producing CRE (IDSA guidelines).

Pharmaceutical Form:

Sterile powder in vial: 2.5 g

Reconstitution:

Reconstitute with 10 mL Sterile Water for Injection, 0.9% Sodium Chloride, or 5% Dextrose. Mix gently (final volume ≈12 mL). Further dilute the entire contents in 50–250 mL compatible infusion fluid. Infuse over 2 hours. Do not mix with other drugs.

Dosage:

Adults (CrCl >50 mL/min):
2.5 g IV every 8 hours.
Duration: 5–14 days (depending on infection).

Renal impairment: Mandatory dose reduction (e.g., 1.25 g q8h for CrCl 31–50 mL/min).
Combination with Aztam: Aztreonam 2 g IV q8h + Zidavi 2.5 g IV q8h (concurrent) for NDM/MBL infections